Literature DB >> 22390691

Immunobiology of antigen-specific immunoglobulin free light chains in chronic inflammatory diseases.

Tom Groot Kormelink1, Philip W Askenase, Frank A Redegeld.   

Abstract

Mast cells are increasingly recognized as critical players in elicitation and maintenance of different inflammatory related disorders, like allergy, autoimmune diseases and cancer. Mast cells maturate within the tissue and are able to adapt to microenvironmental changes. Together with the ability to produce multiple pro- and anti-inflammatory mediators upon activation, mast cells are highly capable of exerting immunomodulatory functions. Cross-linking of receptor bound IgE is the best known mechanism of antigen-specific mast cell activation. In this review we focus on a different route of activation, via immunoglobulin free light chains (FLCs). Here, we describe current knowledge and concepts on FLCs based on preclinical models and data on human subjects, after briefly recapitulating early research findings on FLCs. Furthermore, because FLC research mainly focuses on mast cells, several mast cell mediated pathologies and mouse models for mast cell research will be discussed. Whether targeting of mast cells is beneficial for the treatment of specific disorders has to be addressed in future studies. Specific inhibition of FLC-mediated mast cell activation may be an interesting avenue to treat chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22390691     DOI: 10.2174/138161212800166059

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity.

Authors:  Krzysztof Bryniarski; Wlodzimierz Ptak; Asha Jayakumar; Kerstin Püllmann; Michael J Caplan; Arthit Chairoungdua; Jun Lu; Brian D Adams; Emilia Sikora; Katarzyna Nazimek; Susanna Marquez; Steven H Kleinstein; Panjamaporn Sangwung; Yasuko Iwakiri; Eric Delgato; Frank Redegeld; Bart R Blokhuis; Jacek Wojcikowski; Anna Wladyslawa Daniel; Tom Groot Kormelink; Philip W Askenase
Journal:  J Allergy Clin Immunol       Date:  2013-05-31       Impact factor: 10.793

Review 2.  A subset of AID-dependent B-1a cells initiates hypersensitivity and pneumococcal pneumonia resistance.

Authors:  Phillip W Askenase; Krzysztof Bryniarski; Vipin Paliwal; Frank Redegeld; Thomas Groot Kormelink; Steven Kerfoot; Andrew T Hutchinson; Henk van Loveren; Regis Campos; Atsuko Itakura; Monika Majewska-Szczepanik; Natsuo Yamamoto; Katarzyn Nazimek; Marian Szczepanik; Wold Ptak
Journal:  Ann N Y Acad Sci       Date:  2015-12       Impact factor: 5.691

Review 3.  From Mysterious Supernatant Entity to miRNA-150 in Antigen-Specific Exosomes: a History of Hapten-Specific T Suppressor Factor.

Authors:  Włodzimierz Ptak; Katarzyna Nazimek; Philip W Askenase; Krzysztof Bryniarski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-02-18       Impact factor: 4.291

4.  Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis!

Authors:  Mahin Khatami
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

5.  Antibody Light Chains Dictate the Specificity of Contact Hypersensitivity Effector Cell Suppression Mediated by Exosomes.

Authors:  Katarzyna Nazimek; Philip W Askenase; Krzysztof Bryniarski
Journal:  Int J Mol Sci       Date:  2018-09-07       Impact factor: 5.923

6.  Orally Administered Exosomes Suppress Mouse Delayed-Type Hypersensitivity by Delivering miRNA-150 to Antigen-Primed Macrophage APC Targeted by Exosome-Surface Anti-Peptide Antibody Light Chains.

Authors:  Katarzyna Nazimek; Krzysztof Bryniarski; Wlodzimierz Ptak; Tom Groot Kormelink; Philip W Askenase
Journal:  Int J Mol Sci       Date:  2020-08-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.